Update in HIV infection in organ transplantation

Current Opinion in Organ Transplantation

Volumn 17, Issue 6, 2012, Pages 586-593

  Grossi, Paolo A ^a,b  

^a UNIVERSITY OF INSUBRIA   (Italy)

^b National Center for Transplantation   (Italy)

Author keywords

drug drug interactions; hepatitis B virus infection; hepatitis C virus infection organ transplantation; HIV infection; outcomes

Indexed keywords

CALCINEURIN INHIBITOR; CYTOCHROME P450; EFAVIRENZ; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RAPAMYCIN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; CAUSE OF DEATH; DISEASE SEVERITY; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; ENZYME INHIBITION; HEART TRANSPLANTATION; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY PANCREAS TRANSPLANTATION; KIDNEY TRANSPLANTATION; LEFT VENTRICULAR ASSIST DEVICE; LOW DRUG DOSE; LUNG TRANSPLANTATION; MIXED INFECTION; MODEL FOR END STAGE LIVER DISEASE SCORE; MULTICENTER STUDY (TOPIC); ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PATIENT SELECTION; POST TREATMENT SURVIVAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REOPERATION; REVIEW; SCORING SYSTEM; SURVIVAL RATE; TREATMENT OUTCOME;

DRUG INTERACTIONS; GRAFT SURVIVAL; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HEPATITIS C; HIV INFECTIONS; HUMANS; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LUNG TRANSPLANTATION; ORGAN TRANSPLANTATION; PANCREAS TRANSPLANTATION; PATIENT SELECTION; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT; WAITING LISTS;

EID: 84870237181     PISSN: 10872418     EISSN: 15317013     Source Type: Journal    
DOI: 10.1097/MOT.0b013e3283592684     Document Type: Review

References (80)

1. Mocroft A, Reiss P, Gasiorowski J, et al.; EuroSIDA Study Group. Serious fatal and nonfatal non-AIDS-defining illnesses in Europe. J Acquir Immune Defic Syndr 2010; 55:262-270.
2. Lacombe K, Rockstroh J. HIV and viral hepatitis coinfections: advances and challenges. Gut 2012; 61 (Suppl 1):i47-i58; Review.
3. Jones M, Núñez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012; 32:167-176.
4. Vallet-Pichard A, Mallet V, Pol S. Nonalcoholic fatty liver disease and HIV infection. Semin Liver Dis 2012; 32:158-166.
5. Puoti M, Moioli MC, Travi G, Rossotti R. The burden of liver disease in human immunodeficiency virus-infected patients. Semin Liver Dis 2012; 32:103-113.
6. Ragni MV, Dodson SF, Hunt SC, et al. Liver transplantation in a hemophilia patient with acquired immunodeficiency syndrome. Blood 1999; 93:1113-1114.
7. Roland ME, Barin B, Carlson L, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant 2008; 8:355-365.
8. Cooper C, Kanters S, Klein M, et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS 2011; 25:777-786; Review.
9. Fox AN, Vagefi PA, Stock PG. Liver transplantation in HIV patients. Semin Liver Dis 2012; 32:177-185.
10. Blumberg EA, Stock P, the AST Infectious Diseases Community of Practice. Solid organ transplantation in the HIV-infected patient. Am J Transplant 2009; 9 (Suppl 4):S131-S135.
11. Ragni MV, Eghtesad B, Schlesinger KW, et al. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11:1425-1430. (Pubitemid 43071593)
12. Murillas J, Rimola A, Laguno M, et al., ESLD-HIV Working Group Investigators. The Model For End-Stage Liver Disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study. Liver Transpl 2009; 15:1133-1141.
13. Subramanian A, Sulkowski M, Barin B, et al. MELD score is an important predictor of pretransplantation mortality in HIV-infected liver transplant candidates. Gastroenterology 2010; 138:159-164.
14. Ragni MV, Belle SH, Im K, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188:1412-1420. (Pubitemid 37523925)
15. de Vera ME, Dvorchik I, Tom K, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6:2983-2993.
16. Duclos-Vallee JC, Feray C, Sebagh M, et al. Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2008; 47:407-417. (Pubitemid 351280708)
17. Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: analysis of United Network for Organ Sharing database. Transplantation 2008; 85:359-368. (Pubitemid 351322759)
18. Antonini TM, Sebagh M, Roque-Afonso AM, et al. Fibrosing cholestatic hepatitis in HIV/HCV co-infected transplant patients-usefulness of early markers after liver transplantation. Am J Transplant 2011; 11:1686-1695.
19. Terrault NA, Roland ME, Schiano T, et al., for the Solid Organ Transplantation in HIV: Multi-Site Study Investigators. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18:716-726.
20. Miro JM, Montejo M, Castells L, et al., the Spanish OLT in HIV-Infected Patients Working Group Investigators. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant 2012; 12:1866-1876.
21. Moreno A, Cervera C, Fortún J, et al., OLT-HIV FIPSE Cohort Investigators. Epidemiology and outcome of infections in human immunodeficiency virus/ hepatitis C virus-coinfected liver transplant recipients: a FIPSE/GESIDA prospective cohort study. Liver Transpl 2012; 18:70-81.
22. Gastaca M, Aguero F, Rimola A, et al.; the FIPSE OLT-HIV Investigators. Liver retransplantation in HIV-infected patients: a prospective cohort study. Am J Transplant 2012. doi: 10.1111/j.1600-6143.2012.04142.x. [Epub ahead of print]
23. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis 2012. [Epub ahead of print]
24. Miro JM, Cofan F, Trullas JC, et al. Renal dysfunction in the setting of HIV/AIDS. Curr HIV/AIDS Rep 2012; 9:187-199.
25. Finelli L, Miller JT, Tokars JI, et al. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial 2005; 18:52-61. (Pubitemid 40348277)
26. Vigneau C, Guiard-Schmid JB, Tourret J, et al. The clinical characteristics of HIV-infected patients receiving dialysis in France between 1997 and 2002. Kidney Int 2005; 67:1509-1514. (Pubitemid 40463128)
27. Trullàs JC, Barril G, Cofan F, et al., the Spanish HIV Infection in Dialysis Study Group. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006 - GESIDA 48/05 study. AIDS Res Hum Retroviruses 2008; 24:1229-1235.
28. Trullàs JC, Cofan F, Barril G, et al., Spanish HIV Infection in Dialysis Study Group. Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr 2011; 57:276-283.
29. Stock PG, Barin B, Murphy B, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med 2010; 363:2004-2014;
30. Erratum in: N Engl J Med 2011; 364:1082.
31. Trullas JC, Cofan F, Tuset M, et al. Renal transplantation in HIV-infected patients: 2010 update. Kidney Int 2011; 79:825-842.
32. Kumar MS, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005; 67:1622-1629. (Pubitemid 40463144)
33. Touzot M, Pillebout E, Matignon M, et al. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant 2010; 10:2263-2269.
34. Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med 2010; 362:2336-2337.
35. Fine DM, Perazella MA, Lucas GM, Atta MG. Renal disease in patients with HIV infection: epidemiology, pathogenesis and management. Drugs 2008; 68:963-980. (Pubitemid 351652924)
36. Wai PY, Sollinger HW. Long-term outcomes after simultaneous pancreas-kidney transplant. Curr Opin Organ Transplant 2011; 16:128-134.
37. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IPTR). Clin Transpl 2008:45-56.
38. Toso C, Berney T, Oberholzer J, et al. Pancreas-kidney transplantation in a long-term nonprogressor HIV-infected recipient. Am J Transplant 2003; 3:631-633. (Pubitemid 36612848)
39. Miro JM, Ricart MJ, Trullas JC, et al. Simultaneous pancreas-kidney transplantation in HIV-infected patients: a case report and literature review. Transplant Proc 2010; 42:3887-3891.
40. Akhtar MZ, Patel N, Devaney A, et al. Simultaneous pancreas kidney transplantation in the HIV-positive patient. Transplant Proc 2011; 43:3903-3904.
41. Grossi PA, Righi E, Gasperina DD, et al. Report of four simultaneous pancreas-kidney transplants in HIV-positive recipients with favorable outcomes. Am J Transplant 2012; 12:1039-1045.
42. Schiemann U, Ferhat A, Götzberger M, et al. Prevalence of cholecystolithiasis and its management among kidney/pancreas-transplanted type 1 (insulin-dependent) diabetic patients. Eur J Med Res 2008; 13:127-130. (Pubitemid 351559883)
43. Zareba KM, Lipshultz SE. Cardiovascular complications in patients with HIV infection. Curr Infect Dis Rep 2003; 5:513-520. (Pubitemid 38899185)
44. Rerkpattanapipat P, Wongpraparut N, Jacobs LE, et al. Cardiac manifestations of acquired immunodeficiency syndrome. Arch Intern Med 2000; 160:602-608. (Pubitemid 30140409)
45. Aberg J. Cardiovascular complications in HIV management: past, present, and future. J Acquir Immune Defic Syndr 2009; 50:54-64.
46. Currier JS. Update on cardiovascular complications in HIV infection. Top HIV Med 2009; 17:98-103.
47. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. J Infect Dis 2010; 201:318-330.
48. Tzakis AG, Cooper MH, Dummer JS, et al. Transplantation in HIV+ patients. Transplantation 1990; 49:354-358.
49. Anthuber M, Kemkes BM, Heiss MM, et al. HIV infection after heart transplantation: a case report. J Heart Lung Transplant 1991; 10:611-613.
50. Calabrese F, Angelini A, Cecchetto A, et al. HIV infection in the first heart transplantation in Italy: fatal outcome. Case report. APMIS 1998; 106:470-474. (Pubitemid 28252947)
51. Centers for Disease Control. Human immunodeficiency virus infection transmitted from an organ donor screened for HIV antibody: North Carolina. MMWR Morb Mortal Wkly Rep 1987; 36:306-308.
52. Tambini R, Fiocchi R, Gavazzeni G, et al. Human immunodeficiency virus infection after heart transplantation: development of cardiomyopathy after long term survival. Int J Infect Dis 1997; 2:40-43. (Pubitemid 27497767)
53. Ahn J, Cohen SM. Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation. Liver Transplant 2008; 14: 1603-1608.
54. Gupta S, Markham DW, Mammen PP, et al. Long-term follow-up of a heart transplant recipient with documented seroconversion to HIV-positive status 1 year after transplant. Am J Transplant 2008; 8:893-896. (Pubitemid 351347762)
55. Ison MG, Llata E, Conover CS, et al., HIV-HCV Transplantation Transmission Investigation Team. Transmission of human immunodeficiency virus and hepatitis C virus from an organ donor to four transplant recipients. Am J Transplant 2011; 11:1218-1225.
56. Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003; 348:2323-2328. (Pubitemid 36638106)
57. Bisleri G, Morgan JA, Deng MC, et al. Should HIV-positive recipients undergo heart transplantation? J Thorac Cardiovasc Surg 2003; 126:1639-1640. (Pubitemid 37449201)
58. Uriel N, Jorde UP, Cotarlan V, et al. Heart transplantation in human immunodeficiency virus-positive patients. J Heart Lung Transplant 2009; 28:667-669.
59. Durante-Mangoni E, Maiello C, Sbreglia C. A European first: successful heart transplant in a human immunodeficiency virus-positive recipient. J Heart Lung Transplant 2011; 30:845.
60. Boignard A, Blanc M, Chavanon O. High-urgency priority heart transplantation in HIV-positive patients on life support: breaking barriers? J Heart Lung Transplant 2011; 30:968-969.
61. Castel MA, Pérez-Villa F, Roig E, Miró JM. Heart transplantation in an HIV-1-infected patient with ischemic cardiomyopathy and severe pulmonary hypertension. Rev Esp Cardiol 2011; 64:1066-1067.
62. Castel MA, Pérez-Villa F, Miró JM. Heart transplantation in HIV-infected patients: more cases in Europe. J Heart Lung Transplant 2011; 30:1418.
63. Pelletier SJ, Norman SP, Christensen LL, et al. Review of transplantation in HIV patients during the HAART era. Clin Transpl 2004:63-82.
64. Brucato A, Colombo T, Bonacina E, et al. Fulminant myocarditis during HIV seroconversion: recovery with temporary left ventricular mechanical assistance. Ital Heart J 2004; 5:228-231.
65. Fieno DS, Czer LS, Schwarz ER, et al. Left ventricular assist device placement in a patient with end-stage heart failure and human immunodeficiency virus. Interact Cardiovasc Thorac Surg 2009; 9:919-920.
66. Mehmood S, Blais D, Martin S, Sai-Sudhakar C. Heartmate XVE destination therapy for end-stage heart failure in a patient with human immunodeficiency virus. Interact Cardiovasc Thorac Surg 2009; 9:909-910.
67. Sims DB, Uriel N, González-Costello J, et al. Human immunodeficiency virus infection and left ventricular assist devices: a case series. J Heart Lung Transplant 2011; 30:1060-1064.
68. Kim KK, Factor SM. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol 1987; 18:1293.
69. Mehta NJ, Khan IA, Mehta RN, et al. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest 2000; 118:1133.
70. Humbert M, Sitbon O, Chaouat A, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173:1023.
71. Petrosillo N, Chinello P, Cicalini S. Pulmonary hypertension in individuals with HIV infection. AIDS 2006; 20:2128.
72. Bertani A, Grossi P, Vitulo P, et al. Successful lung transplantation in an HIV- and HBV-positive patient with cystic fibrosis. Am J Transplant 2009; 9:2190-2196.
73. Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007; 7:2816-2820. (Pubitemid 350045781)
74. Thomas LD, Miller GG; AST Infectious Diseases Community of Practice. Interactions between antiinfective agents and immunosuppressants. Am J Transplant 2009; 9 (Suppl 4):S263-S266.
75. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9:1946-1952.
76. Fischereder M, Luckow B, Hocher B, et al. CC chemokine receptor 5 and renal transplant survival. Lancet 2001; 357:1758-1761. (Pubitemid 32524207)
77. Heidenhain C, Puhl G, Moench C, et al. Chemokine receptor 5 Delta32 mutation reduces the risk of acute rejection in liver transplantation. Ann Transplant 2009; 14:36-44.
78. Reshef R, Luger SM, Hexner EO, et al. Blockade of lymphocyte chemotaxis in visceral graft-versus-host disease. N Engl J Med 2012; 367:135-145.
79. Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-1628.
80. Mallolas J, Pol S, Rivero A, et al. Boceprevir plus peginterferon/ ribavirin for the treatment of HCV/HIV co-infected patients: end of treatment (week 48) interim results [abstract 50]. Program and abstracts of the 47th Annual Meeting of the European Association for the Study of the Liver; 18-22 April 2012; Barcelona, Spain.